Combination therapy with cholinesterase inhibitors and memantine for alzheimer's disease: A systematic review and meta-Analysis

Shinji Matsunaga, Taro Kishi, Nakao Iwata

研究成果: Article

35 引用 (Scopus)

抄録

Background: We performed an updated meta-Analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease. Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects. Results: Seven studies (total n = 2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference = 0.13), activity of daily living scores (standardized mean difference = 0.10), and global assessment scores (standardized mean difference = 0.15). In addition, cognitive function scores (standardized mean difference = 0.13, P = .06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects. Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated..

元の言語English
ページ(範囲)1-11
ページ数11
ジャーナルInternational Journal of Neuropsychopharmacology
18
発行部数5
DOI
出版物ステータスPublished - 01-03-2015

Fingerprint

Memantine
Cholinesterase Inhibitors
Meta-Analysis
Alzheimer Disease
Activities of Daily Living
Cognition
Therapeutics
Individuality
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

これを引用

@article{ec14ce6e6d3d42ac8996971200f23d7d,
title = "Combination therapy with cholinesterase inhibitors and memantine for alzheimer's disease: A systematic review and meta-Analysis",
abstract = "Background: We performed an updated meta-Analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease. Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects. Results: Seven studies (total n = 2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference = 0.13), activity of daily living scores (standardized mean difference = 0.10), and global assessment scores (standardized mean difference = 0.15). In addition, cognitive function scores (standardized mean difference = 0.13, P = .06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects. Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated..",
author = "Shinji Matsunaga and Taro Kishi and Nakao Iwata",
year = "2015",
month = "3",
day = "1",
doi = "10.1093/ijnp/pyu115",
language = "English",
volume = "18",
pages = "1--11",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "5",

}

TY - JOUR

T1 - Combination therapy with cholinesterase inhibitors and memantine for alzheimer's disease

T2 - A systematic review and meta-Analysis

AU - Matsunaga, Shinji

AU - Kishi, Taro

AU - Iwata, Nakao

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: We performed an updated meta-Analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease. Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects. Results: Seven studies (total n = 2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference = 0.13), activity of daily living scores (standardized mean difference = 0.10), and global assessment scores (standardized mean difference = 0.15). In addition, cognitive function scores (standardized mean difference = 0.13, P = .06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects. Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated..

AB - Background: We performed an updated meta-Analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease. Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects. Results: Seven studies (total n = 2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference = 0.13), activity of daily living scores (standardized mean difference = 0.10), and global assessment scores (standardized mean difference = 0.15). In addition, cognitive function scores (standardized mean difference = 0.13, P = .06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects. Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated..

UR - http://www.scopus.com/inward/record.url?scp=84931266099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931266099&partnerID=8YFLogxK

U2 - 10.1093/ijnp/pyu115

DO - 10.1093/ijnp/pyu115

M3 - Article

C2 - 25548104

AN - SCOPUS:84931266099

VL - 18

SP - 1

EP - 11

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 5

ER -